Compare BridgeBio Pharma Inc (BBIO) vs Zillow Group Inc Class C (Z) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Zillow Group Inc. (Z) trades at $32.19 with no daily change, reflecting a bearish technical signal amid ongoing class action lawsuits. The company shows improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though net margins remain thin at 2.27%. Valuation ratios are elevated with a P/E of 127.4, while analyst consensus targets $57.67, implying significant upside if legal and operational risks subside.

The stock presents a high-risk, high-reward scenario. Positive earnings beats and projected margin expansion to 2.26% in 2026 support bullish fundamentals, but legal overhangs and negative cash flow trends pose near-term headwinds. Institutional sentiment is mixed with 46% buy ratings, suggesting cautious optimism contingent on resolution of litigation and execution on growth initiatives.